Efficacy and safety of tacrolimus compared with ciclosporin a in renal transplantation: Three-year observational results

Bernhard K. Krämer, Domingo Del Castillo, Raimund Margreiter, Heide Sperschneider, Christoph J. Olbricht, Joaquín Ortuño, Urban Sester, Ulrich Kunzendorf, Karl Heinz Dietl, Vittorio Bonomini, Paolo Rigotti, Claudio Ronco, Jose M. Tabernero, Manuel Rivero, Bernhard Banas, Ferdinand Mühlbacher, Manuel Arias, Giuseppe Montagnino

Research output: Contribution to journalArticlepeer-review


Background. The European tacrolimus versus ciclosporin A microemulsion (CsA-ME) renal transplantation study showed that tacrolimus was significantly more effective in preventing acute rejection and had a superior cardiovascular risk profile at 6 months. Methods. The endpoints of this investigator-initiated, observational, 36-month follow-up were acute rejection incidence rates, rates of patient and graft survival and renal function. An additional analysis was performed using the combined endpoints BPAR, graft loss and patient death. Data available from the original ITT population (557 patients; 286 tacrolimus and 271 CsA-ME) were analysed. Results. A total of 231 tacrolimus and 217 CsA-ME patients participated. At 36 months, Kaplan-Meier-estimated BPAR-free survival rates were 78.8% in the tacrolimus group and 60.6% in the CsA-ME group, graft survival rates were 88.0% and 86.9% and patient survival rates were 96.6% and 96.7%, respectively. The estimated combined endpoint-free survival rate was 71.4% with tacrolimus and 55.4% with CsA-ME (P ≤ 0.001, chi-square test). Significantly more CsA-ME patients crossed over to tacrolimus during the 3-year follow-up: 21.2% versus 2.6%, P ≤ 0.0001, chi-square test. Most patients in the tacrolimus arm discontinued steroids and received monotherapy and fewer tacrolimus patients remained on a triple regimen. Mean serum creatinine concentration was 145.4 ± 90.9 μmol/L with tacrolimus and 149.0 ± 92.1 μmol/L with CsA-ME. Significantly more CsA-ME patients had a classified cholesterol value >6 mmol/L (26.3% versus 12.6%, P ≤ 0.0003, chi-square test). Conclusions. Patients treated with tacrolimus had significantly higher combined endpoint-free survival rates and lower acute rejection rates with less immunosuppressive medication at 36 months.

Original languageEnglish
Pages (from-to)2386-2392
Number of pages7
JournalNephrology Dialysis Transplantation
Issue number7
Publication statusPublished - Jul 2008


  • Acute rejection
  • Calcineurin inhibitors
  • Follow-up
  • Graft survival
  • Patient survival

ASJC Scopus subject areas

  • Nephrology
  • Transplantation


Dive into the research topics of 'Efficacy and safety of tacrolimus compared with ciclosporin a in renal transplantation: Three-year observational results'. Together they form a unique fingerprint.

Cite this